DOJ awards $2.5M contract for influenza vaccine to Seqirus USA Inc. for FCI Texarkana inmates

Contract Overview

Contract Amount: $2,542 ($2.5K)

Contractor: Seqirus USA Inc

Awarding Agency: Department of Justice

Start Date: 2025-09-30

End Date: 2026-09-30

Contract Duration: 365 days

Daily Burn Rate: $7/day

Competition Type: FULL AND OPEN COMPETITION

Pricing Type: FIRM FIXED PRICE

Sector: Healthcare

Official Description: 2026 INFLUENZA VIRUS VACCINE FOR FCI TEXARKANA INMATES

Place of Performance

Location: SWIFTWATER, MONROE County, PENNSYLVANIA, 18370

State: Pennsylvania Government Spending

Plain-Language Summary

Department of Justice obligated $2,541.6 to SEQIRUS USA INC for work described as: 2026 INFLUENZA VIRUS VACCINE FOR FCI TEXARKANA INMATES Key points: 1. Contract value of $2.5M for a one-year supply of influenza vaccine. 2. Awarded under full and open competition, suggesting a competitive bidding process. 3. The contract is a delivery order against a larger Basic Ordering Agreement (BOA). 4. The fixed-price nature of the contract shifts risk to the contractor. 5. The service is essential for public health within a correctional facility. 6. The contractor, Seqirus USA Inc., is a known pharmaceutical manufacturer.

Value Assessment

Rating: good

The contract value of $2.5 million for a one-year supply of influenza vaccine appears reasonable given the scale of a federal correctional facility. Benchmarking against similar public health contracts for correctional institutions or large-scale vaccine procurements would provide further context. The firm-fixed-price structure indicates that the government has secured a defined cost for the service, which is a positive indicator for budget predictability.

Cost Per Unit: N/A

Competition Analysis

Competition Level: full-and-open

This contract was awarded under full and open competition, indicating that all responsible sources were permitted to submit a bid. The specific number of bidders is not provided, but this method generally fosters price discovery and encourages competitive pricing. The government likely sought the best value proposition in terms of price, quality, and delivery.

Taxpayer Impact: Full and open competition is beneficial for taxpayers as it typically leads to lower prices and better terms due to the pressure of multiple bidders vying for the contract.

Public Impact

Inmates at Federal Correctional Institution (FCI) Texarkana will receive essential influenza vaccinations. The contract ensures a critical public health service is delivered within a federal correctional setting. The geographic impact is localized to FCI Texarkana, Texas. The contract supports the pharmaceutical manufacturing sector through its procurement.

Waste & Efficiency Indicators

Waste Risk Score: 50 / 10

Warning Flags

Potential for price fluctuations in future contract renewals if competition diminishes.
Dependence on a single supplier for a critical health commodity for the duration of the contract.

Positive Signals

Awarded through full and open competition, indicating a robust bidding process.
Firm-fixed-price contract provides cost certainty for the government.
Contract addresses a critical public health need within a federal facility.

Sector Analysis

The pharmaceutical preparation manufacturing sector is a vital component of the healthcare industry, responsible for producing a wide range of medications and vaccines. Federal agencies, including the Department of Justice, are significant purchasers of pharmaceutical products to meet the healthcare needs of various populations, such as federal inmates. This contract for influenza vaccines fits within the broader category of public health procurement, ensuring disease prevention and management within government-run facilities. Comparable spending benchmarks would involve analyzing other large-scale vaccine procurements by federal agencies or state health departments.

Small Business Impact

The provided data indicates that small business participation was not a specific set-aside for this contract (ss: false, sb: false). While this contract was awarded under full and open competition, there is no explicit information on subcontracting opportunities for small businesses. The primary contractor, Seqirus USA Inc., is a large pharmaceutical company, suggesting that direct subcontracting to small businesses for the core vaccine supply is unlikely, though support services could potentially involve smaller firms.

Oversight & Accountability

Oversight for this contract would primarily fall under the Department of Justice's Bureau of Prisons (BOP) contracting and program management officials. Accountability measures are embedded in the firm-fixed-price contract terms, requiring delivery of specified vaccine quantities by the deadline. Transparency is generally maintained through federal contract databases like FPDS. Inspector General jurisdiction would apply if any fraud, waste, or abuse were suspected in the procurement or fulfillment process.

Related Government Programs

Federal Prison System Health Services
Bureau of Prisons Pharmaceutical Procurement
Influenza Vaccine Procurement Programs
Public Health Services in Correctional Facilities

Risk Flags

Potential for supply chain disruptions
Contractor performance risk
Public health risk in congregate settings

Frequently Asked Questions

What is this federal contract paying for?

Department of Justice awarded $2,541.6 to SEQIRUS USA INC. 2026 INFLUENZA VIRUS VACCINE FOR FCI TEXARKANA INMATES

Who is the contractor on this award?

The obligated recipient is SEQIRUS USA INC.

Which agency awarded this contract?

Awarding agency: Department of Justice (Federal Prison System / Bureau of Prisons).

What is the total obligated amount?

The obligated amount is $2,541.6.

What is the period of performance?

Start: 2025-09-30. End: 2026-09-30.

What is the historical spending pattern for influenza vaccines by the Federal Prison System?

Analyzing historical spending patterns for influenza vaccines by the Federal Prison System (FPS) is crucial for understanding long-term trends and budget predictability. While specific historical data for this exact contract is not provided, general trends in federal vaccine procurement can be inferred. Agencies like the FPS typically procure vaccines annually to meet the needs of their inmate populations. Spending can fluctuate based on vaccine availability, pricing from manufacturers, the number of inmates served, and public health recommendations regarding vaccination campaigns. For instance, during pandemic years or periods of high influenza activity, demand and potentially costs might increase. Comparing current contract values to previous years' expenditures, adjusted for inflation and volume, would reveal whether the current $2.5 million award represents an increase, decrease, or stable spending level for this essential service.

How does the price per dose of this influenza vaccine compare to market rates or other federal procurements?

Determining the precise price per dose is not possible without knowing the quantity of vaccine units procured under this $2.5 million contract. However, the contract's firm-fixed-price nature suggests that the government has negotiated a set price for the total requirement. To benchmark this, one would need to compare the implied price per dose (if calculable) against publicly available data for similar influenza vaccine procurements. This could include contracts awarded by other federal agencies (e.g., Department of Defense, Department of Veterans Affairs) or state and local health departments. Factors influencing price per dose include the specific vaccine formulation (e.g., quadrivalent, high-dose), the manufacturer, the volume purchased, and the timing of the procurement. A higher volume typically leads to a lower price per unit. Without the quantity, a direct comparison is speculative, but the full and open competition award mechanism suggests an effort to secure competitive pricing.

What is Seqirus USA Inc.'s track record in supplying vaccines to federal agencies?

Seqirus USA Inc. is a significant player in the influenza vaccine market and has a history of supplying vaccines to government entities. As a subsidiary of CSL Limited, it has the capacity and experience to handle large-scale federal contracts. Federal procurement databases would likely show past awards to Seqirus for influenza vaccines and other biological products. Assessing their track record would involve reviewing past performance evaluations, on-time delivery rates, and any instances of contract disputes or quality issues. Agencies often consider a contractor's past performance as a key factor in source selection. Given that Seqirus is a known supplier, it is probable they have fulfilled similar requirements for federal agencies, including potentially other correctional systems or military branches, demonstrating their capability to meet stringent federal standards.

What are the potential risks associated with this contract, and how are they mitigated?

Potential risks for this contract include supply chain disruptions affecting vaccine availability, potential for adverse reactions (though rare and managed through standard medical protocols), and the possibility of the contractor failing to meet delivery schedules. Mitigation strategies are embedded within the contract structure and agency oversight. The firm-fixed-price nature shifts financial risk to the contractor. The contract's duration (one year) limits long-term exposure. The Department of Justice's Bureau of Prisons will monitor performance, ensuring timely delivery and adherence to specifications. Furthermore, the use of a reputable, established manufacturer like Seqirus USA Inc. reduces the risk of supply failure. Contingency planning for vaccine shortages or distribution issues is also a standard practice within public health initiatives.

How does this contract contribute to the overall public health mission of the Department of Justice?

This contract directly supports the Department of Justice's (DOJ) public health mission by ensuring the provision of a critical preventive healthcare service to the federal inmate population. Influenza is a highly contagious respiratory illness, and vaccination is the most effective means of prevention. In a congregate setting like a federal prison, the rapid spread of influenza can lead to significant health complications, outbreaks, and strain on medical resources. By securing a reliable supply of influenza vaccines, the DOJ mitigates these risks, protecting the health and well-being of inmates, who are under the government's care. This also contributes to the broader public health goal of reducing community transmission of influenza, as individuals re-entering society from correctional facilities can carry and spread the virus.

Industry Classification

NAICS: Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing

Product/Service Code: MEDICAL/DENTAL/VETERINARY EQPT/SUPP

Competition & Pricing

Extent Competed: FULL AND OPEN COMPETITION

Solicitation Procedures: NEGOTIATED PROPOSAL/QUOTE

Pricing Type: FIRM FIXED PRICE (J)

Evaluated Preference: NONE

Contractor Details

Address: 25 DEFOREST AVE STE 200, SUMMIT, NJ, 07901

Business Categories: Category Business, Corporate Entity Not Tax Exempt, Foreign Owned, Foreign-Owned and U.S.-Incorporated Business, Manufacturer of Goods, Not Designated a Small Business, Special Designations

Financial Breakdown

Contract Ceiling: $2,542

Exercised Options: $2,542

Current Obligation: $2,542

Contract Characteristics

Commercial Item: COMMERCIAL PRODUCTS/SERVICES

Cost or Pricing Data: NO

Parent Contract

Parent Award PIID: 36E79725D0006

IDV Type: IDC

Timeline